A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

• Drug: NXL104
  IV Solution
• Drug: CAZ104
  IV Solution
• Drug: Placebo
  IV saline

• Experimental: NXL104
  Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
  Intervention: Drug: NXL104
• Placebo Comparator: Placebo
  Three Japanese subjects to receive placebo IV doses
  Intervention: Drug: Placebo
• Experimental: Ceftazidime NXL104 (CAZ104)
  Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
  Intervention: Drug: CAZ104

Inclusion Criteria:

• To be considered as 'Japanese', both of the volunteer's parents, and all grandparents must be Japanese. The volunteer must have been born in Japan, have a valid Japanese passport and must not have lived outside Japan for more than 5 years
• Have a body mass index (BMI) between 17 and 27 kg/m2 inclusive and weigh at least 45 kg and no more than 100 kg.
• Females must not be lactating, and must be of non-childbearing potential (post-menopausal at least 12 months or documented irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation

Exclusion Criteria:

• History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
• Symptoms of a clinically significant illness in the 3 months before the study
• History of hypersensitivity (eg, anaphylaxis), serious allergy, or any serious reaction to carbapenem, cephalosporins, or other ?-lactam antibiotics
• Use within 14 days prior to the first study dose of any over-the-counter (including St. John's Wort or any herbal products) or prescription medication
• Smoker of more than 5 cigarettes/day or equivalent use of nicotine products during the previous 3 months